www.fdanews.com/articles/69705-imarx-therapeutics-completes-7-million-financing
ImaRx Therapeutics Completes $7 Million Financing
March 10, 2005
ImaRx Therapeutics, a biopharmaceutical company developing NanoInvasive therapies for stroke and cancer, has announced the placement of 2.3 million shares of common stock raising gross proceeds of $7 million. The company will use the net proceeds to, among other items, fund the clinical trials of its lead technology, SonoLysis, which incorporates MRX-815 nanobubbles and ultrasound to dissolve blood clots. A Phase I/II clinical trial for the treatment of peripheral arterial occlusions as well as a Phase II trial for stroke is scheduled to begin in second quarter 2005.